Antitumor effects of Nafamostat mesilate on head and neck squamous cell carcinoma

Auris Nasus Larynx

Volumn 34, Issue 4, 2007, Pages 487-491

  Yamashita, Yukiko ^a   Ishiguro, Yukari ^a   Sano, Daisuke ^a   Kimura, Machiko ^a   Fujita, Kyoko ^a   Yoshida, Takafumi ^a   Horiuchi, Choichi ^a   Taguchi, Takahide ^a   Matsuda, Hideki ^a   Mikami, Yasukazu ^a   Tsukuda, Mamoru ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti angiogenic; Head and neck cancer; Matrix metalloproteinases; Metastasis

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; NAFAMSTAT MESILATE; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA;

ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GUANIDINES; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGEAL NEOPLASMS; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; TUMOR STEM CELL ASSAY; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VULVAR NEOPLASMS;

EID: 35348971862     PISSN: 03858146     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.anl.2006.12.002     Document Type: Article

References (21)

1. Young M.R. Protective mechanisms of head and neck squamous cell carcinomas from immune assault. Head Neck 28 (2006) 462-470
2. Liotta L.A., and Stetler-Stevenson W.G. Tumor invasion and metastasis: an imbalance of positive and negative regulation. Cancer Res 51 (1991) 5054-5059
3. Lukashev M.E., and Werb Z. ECM signalling: orchestrating cell behaviour and misbehaviour. Trends Cell Biol 8 (1998) 437-441
4. Duffy M.J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metast 10 (1992) 145-155
5. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., and Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 284 (1980) 67-68
6. Uchima Y., Sawada T., Nishihara T., Maeda K., Ohira M., and Hirakawa K. Inhibition and mechanism of action of a protease inhibitor in human pancreatic cancer cells. Pancreas 29 (2004) 123-131
7. Aoyama T., and Ino Y. Pharmacological studies of FUT-175, Nafamostat mesilate. Jpn J Pharmacol 35 (1884) 203-227
8. Fujii S., and Hitomi Y. New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kallikrein and trypsin. Biochim Biophys Acta 661 (1981) 342-345
9. Hitomi Y., Ikari N., and Fujii S. Inhibitory effect of a new synthetic protease inhibitor (FUT-175) on the coagulation system. Haemostasis 15 (1985) 164-168
10. Nakatsuka M., Asagiri K., Noguchi S., Habara T., and Kudo T. Nafamostat mesilate, a serine protease inhibitor, suppresses lipopolysaccharide-induced nitric oxide synthesis and apoptosis in cultured human trophoblasts. Life Sci 67 (2000) 1243-1250
11. Kimura T., Fuchimoto S., Iwagaki H., Hizuta A., and Orita K. Inhibitory effect of Nafamostat mesilate on metastasis into the livers of mice and on invasion of the extracellular matrix by cancer cells. J Int Med Res 20 (1992) 343-352
12. Yoon W.H., Jung Y.J., Kim T.D., Li G., Park B.J., Kim J.Y., et al. Gabexate mesilate inhibits colon cancer growth, invasion, and metastasis by reducing matrix metalloproteinases and angiogenesis. Clin Cancer Res 10 (2004) 4517-4526
13. Iacopetta B.J., Grieu F., Horisberger M., and Sunahara G.I. Epidermal growth factor in human and bovine milk. Acta Paediatr 81 (1992) 287-291
14. Groves R.W., Allen M.H., Ross E.L., Ahsan G., Barker J.N., and MacDonald D.M. Expression of selectin ligands by cutaneous squamous cell carcinoma. Am J Pathol 143 (1993) 1220-1225
15. Ishiyama M., Miyazono Y., Sasamoto K., Ohkura Y., and Ueno K. A highly water-soluble disulfonated tetrazolium salt as a chromogenic indicator for NADH as well as cell viability. Talanta 44 (1997) 1299-1305
16. Rosenthal E.L., and Matrisian L.M. Matrix metalloproteases in head and neck cancer. Head Neck 28 (2006) 639-648
17. Nagakawa Y., Aoki T., Kasuya K., Tsuchida A., and Koyanagi Y. Histologic features of venous invasion, expression of vascular endothelial growth factor and matrix metalloproteinase-2 and matrix metalloproteinase-9, and the relation with liver metastasis in pancreatic cancer. Pancreas 24 (2002) 169-178
18. Akhurst R.J., and Derynck R. TGF-beta signaling in cancer-a double-edged sword. Trends Cell Biol 11 (2001) 44-51
19. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
20. Stetler-Stevenson W.G. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103 (1999) 1237-1241
21. FUTHAN™ (Nafamostat mesilate) Injection. Japan Prescribing Information. Torii Pharmaceutical Co. Ltd., Tokyo, Japan, October, 2006.